Tag: rivaroxaban
Paediatric trial finds rivaroxaban similar to standard anticoagulation in treatment of...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing paediatric patients (aged birth to...
CASSINI trial results inconclusive on rivaroxaban effects in high-risk ambulatory cancer...
The CASSINI trial found that treatment with rivaroxaban did not significantly reduce the incidence of thromboembolism or death caused by thromboembolism in high-risk ambulatory...
Study proves need for anticoagulant strategy post discharge for hospitalised, at-risk...
Alex C Spyropoulos, from Feinstein Institute for Medical Research (New York, USA), has presented an anticoagulant treatment strategy to reduce non-fatal blood clots and...
Edoxaban emerges as alternative to dalteparin for cancer-associated VTE
A new analysis has identified patient populations with cancer-associated venous thromboembolism (VTE) who could benefit from treatment with oral anticoagulant edoxaban, taken once daily.
Daiichi...
FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...
Canadian study finds rivaroxaban more effective at preventing recurrent blood clots...
A Canadian-led international research team has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of...
Two new real-world studies confirm positive efficacy and safety profile of...
Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...
